20000623 9-8

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 31/00

A2

(11) International Publication Number: WO 00/54763

(43) International Publication Date: 21 September 2000 (21.09.00)

(21) International Application Number: PCT/US00/06987

(22) International Filing Date: 16 March 2000 (16.03.00)

(30) Priority Data:
60/125,201 18 March 1999 (18.03.99) US

(71) Applicant: GENELABS TECHNOLOGIES, INC. [US/US]; 505 Penobscot Drive, Redwood City, CA 94063 (US).

(72) Inventors: PARASRAMPURIA, Jagdish; 4012 Riddle Court, Bridgewater, NJ 08807 (US). YONKER, Maxine, B.; 427 Lakeview Way, Emerald Hills, CA 94062 (US). SCHWARTZ, Kenneth, E.; 511 Virginia Avenue, San Mateo, CA 94402 (US). GURWITH, Marc, J.; 13157 La Paloma Road, Los Altos, CA 94022 (US).


(74) Agents: GORTHEY, LeeAnn et al.; Dehlinger & Associates, P.O. Box 60850, Palo Alto, CA 94306-0850 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: DHEA COMPOSITION AND METHOD



(57) Abstract

Disclosed are improved pharmaceutical formulations comprising dehydroepiandrosterone (DHEA), enriched in selected polymorphic forms, for therapeutic applications. In one embodiment, the formulation comprises, in solid form, DHEA, at least 85% of which is present as a single polymorph selected from the form I polymorph or the form II polymorph, and at least one pharmaceutical excipient. Methods for making and using such compositions are also disclosed.